tiprankstipranks

MBX Biosciences sees cash runway into mid-2027

MBX Biosciences sees cash runway into mid-2027

As of September 30, 2024, MBX had cash, cash equivalents and marketable securities of $277.1 million compared to $80.7 million as of December 31, 2023. Based on its current operating plan, management expects the combined cash, cash equivalents and marketable securities balance to fund operations into mid-2027.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Questions or Comments about the article? Write to editor@tipranks.com